Bioclinica acquires clinical trial AI firm

By staff writers

January 6, 2021 -- Clinical trial management services firm Bioclinica has acquired Saliency, the developer of an artificial intelligence (AI)-based software that speeds medical image interpretation to help support pharmaceutical and medical device clients in clinical trials.

Saliency's platform uses proprietary algorithms to build and train AI models quickly from a small number of deidentified images. The models can be used to screen, redact, or interpret medical images to support numerous therapeutic areas.

The AI capability will be embedded into Bioclinica's current and future imaging products and services for research sponsors and clinical research organizations.

Copyright © 2021

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking